Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Sintilimab in Advanced Solid Tumors (Ib/II)
CTR20190514Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, sintilimab in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), endometrial cancer (EC), gastric adenocarcinoma, sponsored by HUTCHMED. Started Mar 2019; status: completed.
02
Drugs
fruquintinibsintilimab
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)renal cell carcinoma (RCC)endometrial cancer (EC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20190514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190514.